Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VERVE 201

Next Previous
X
Search
Drug Profile

VERVE 201

Alternative Names: ANGPTL3 targeted gene editing therapy - Verve Therapeutics; VERVE-201

Latest Information Update: 25 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Broad Institute; Harvard University
  • Developer Verve Therapeutics
  • Class Antihyperlipidaemics; Gene therapies; RNA
  • Mechanism of Action ANGPTL3 protein expression inhibitors; Gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Hypercholesterolaemia
  • Preclinical Hyperlipoproteinaemia type IIa

Most Recent Events

  • 30 Oct 2024 Phase-I clinical trials in Hypercholesterolaemia (Treatment-experienced) in United Kingdom, Canada (IV) (NCT06451770)
  • 23 May 2024 Verve Therapeutics plans a phase Ib trial for Hyperlipoproteinaemia type IIa in H2 2024
  • 31 Oct 2023 Beam Therapeutics enters into a collaboration agreement with Eli Lilly for PCSK9 and ANGPTL3 programs including VERVE 101

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top